FDA ap­proves Re­by­ota, Fer­ring's poop-based drug to fight C. diff in­fec­tion

The FDA ap­proved Fer­ring Phar­ma­ceu­ti­cals’ Re­by­ota drug on Wednes­day, a poop-based drug im­plant that can pre­vent the re­cur­rence of Clostrid­ioides dif­fi­cile in­fec­tion.

While the use of fe­cal mi­cro­bio­ta trans­plan­ta­tion (FMT) — re­plen­ish­ing a pa­tient’s gut with bac­te­ria from healthy fe­ces — has al­ready been hap­pen­ing with­out an FDA-ap­proved prod­uct, Re­by­ota is the first live bio­ther­a­peu­tic drug ap­proved by the agency to fight the po­ten­tial­ly dead­ly in­fec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.